Ongoing and upcoming clinical trials of metformin, mTOR inhibitors and senescent cell-killing drugs could prove that ageing and ageing-related diseases are viable drug discovery indications.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Multivariate genome-wide analysis of aging-related traits identifies novel loci and new drug targets for healthy aging
Nature Aging Open Access 07 August 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Anti-ageing pipeline starts to mature. Nat Rev Drug Discov 17, 609–612 (2018). https://doi.org/10.1038/nrd.2018.134
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.134